[Application Status of Hypoxia Mimetic Agents in Bone Tissue Engineering]

Overview

Journal Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi

Specialty General Surgery

Date 2020 Sep 15

PMID 32929915

Citations 1

Authors

Sicong Ren

Yiping Liu

Yanlin Zhu

Yingying Wang

Manxuan Liu

Yanmin Zhou

Affiliations

Soon will be listed here.

Abstract

Objective: To summarize the application status of hypoxia mimetic agents in bone tissue engineering.

Methods: The related literature about the hypoxia mimetic agents in bone tissue engineering was reviewed and analyzed. And the application status and progress of hypoxia mimetic agents in bone tissue engineering were retrospectively analyzed.

Results: Hypoxia mimetic agents have the same effect as hypoxia in up-regulating the level of hypoxia inducible factor 1α (HIF-1α). The combination of hypoxia mimetic agents and scaffolds can up-regulate the level of HIF-1α in bone tissue engineering, thus promoting early vascularization and bone regeneration of the bone defect area, which provides a new idea for using bone tissue engineering to repair bone defect. At present, the commonly used hypoxia mimetic agents include iron chelating agents, oxoglutarate competitive analogues, proline hydroxylase inhibitors, .

Conclusion: Hypoxia mimetic agents have a wide application prospect in bone tissue engineering, but they have been used in bone tissue engineering for a short time, more attention should be paid to their possible side effects. In the future research, the hypoxia mimetic agents should be developed in the direction of higher targeting specificity and safety, and the exact mechanism of hypoxia mimetic agents in promoting bone regeneration should be further explored.

Citing Articles

The Role of HIF-1α in Bone Regeneration: A New Direction and Challenge in Bone Tissue Engineering.

You J, Liu M, Li M, Zhai S, Quni S, Zhang L Int J Mol Sci. 2023; 24(9).

PMID: 37175732 PMC: 10179302. DOI: 10.3390/ijms24098029.

References

Thirunavukkarasu M, Selvaraju V, Rao Dunna N, Foye J, Joshi M, Otani H . Simvastatin treatment inhibits hypoxia inducible factor 1-alpha-(HIF-1alpha)-prolyl-4-hydroxylase 3 (PHD-3) and increases angiogenesis after myocardial infarction in streptozotocin-induced diabetic rat. Int J Cardiol. 2013; 168(3):2474-80. DOI: 10.1016/j.ijcard.2013.03.005. View

Li Y, Han W, Wu Y, Zhou K, Zheng Z, Wang H . Stabilization of Hypoxia Inducible Factor-1α by Dimethyloxalylglycine Promotes Recovery from Acute Spinal Cord Injury by Inhibiting Neural Apoptosis and Enhancing Axon Regeneration. J Neurotrauma. 2019; 36(24):3394-3409. DOI: 10.1089/neu.2018.6364. View

Yoshizawa S, Brown A, Barchowsky A, Sfeir C . Magnesium ion stimulation of bone marrow stromal cells enhances osteogenic activity, simulating the effect of magnesium alloy degradation. Acta Biomater. 2014; 10(6):2834-42. DOI: 10.1016/j.actbio.2014.02.002. View

Guzey S, Aykan A, Ozturk S, Avsever H, Karslioglu Y, Ertan A . The Effects of Desferroxamine on Bone and Bone Graft Healing in Critical-Size Bone Defects. Ann Plast Surg. 2016; 77(5):560-568. DOI: 10.1097/SAP.0000000000000679. View

Saito T, Tabata Y . Hypoxia-induced angiogenesis is increased by the controlled release of deferoxiamine from gelatin hydrogels. Acta Biomater. 2014; 10(8):3641-9. DOI: 10.1016/j.actbio.2014.04.021. View

Fu O, Hou M, Yang S, Huang S, Lee W . Cobalt chloride-induced hypoxia modulates the invasive potential and matrix metalloproteinases of primary and metastatic breast cancer cells. Anticancer Res. 2009; 29(8):3131-8. View

Wang W, Liu Y, Yang C, Qi X, Li S, Liu C . Mesoporous bioactive glass combined with graphene oxide scaffolds for bone repair. Int J Biol Sci. 2019; 15(10):2156-2169. PMC: 6775301. DOI: 10.7150/ijbs.35670. View

Wu C, Zhou Y, Xu M, Han P, Chen L, Chang J . Copper-containing mesoporous bioactive glass scaffolds with multifunctional properties of angiogenesis capacity, osteostimulation and antibacterial activity. Biomaterials. 2012; 34(2):422-33. DOI: 10.1016/j.biomaterials.2012.09.066. View

Kim S, Yang E . Recent Advances in Developing Inhibitors for Hypoxia-Inducible Factor Prolyl Hydroxylases and Their Therapeutic Implications. Molecules. 2015; 20(11):20551-68. PMC: 6332328. DOI: 10.3390/molecules201119717. View

10.

Drager J, Ramirez-Garcialuna J, Kumar A, Gbureck U, Harvey E, Barralet J . Hypoxia Biomimicry to Enhance Monetite Bone Defect Repair. Tissue Eng Part A. 2017; 23(23-24):1372-1381. DOI: 10.1089/ten.TEA.2016.0526. View

11.

Zhou M, Hou J, Li Y, Mou S, Wang Z, Horch R . The pro-angiogenic role of hypoxia inducible factor stabilizer FG-4592 and its application in an in vivo tissue engineering chamber model. Sci Rep. 2019; 9(1):6035. PMC: 6465281. DOI: 10.1038/s41598-019-41924-5. View

12.

Maes C, Carmeliet G, Schipani E . Hypoxia-driven pathways in bone development, regeneration and disease. Nat Rev Rheumatol. 2012; 8(6):358-66. DOI: 10.1038/nrrheum.2012.36. View

13.

Sun X, Wei Y . The role of hypoxia-inducible factor in osteogenesis and chondrogenesis. Cytotherapy. 2009; 11(3):261-7. DOI: 10.1080/14653240902824765. View

14.

Baghaban Eslaminejad M, Mirzadeh H, Mohamadi Y, Nickmahzar A . Bone differentiation of marrow-derived mesenchymal stem cells using beta-tricalcium phosphate-alginate-gelatin hybrid scaffolds. J Tissue Eng Regen Med. 2008; 1(6):417-24. DOI: 10.1002/term.49. View

15.

Zhang Y, Huang J, Wang C, Zhang Y, Hu C, Li G . Application of HIF-1α by gene therapy enhances angiogenesis and osteogenesis in alveolar bone defect regeneration. J Gene Med. 2016; 18(4-6):57-64. DOI: 10.1002/jgm.2876. View

16.

Zhang D, Ren L . [DEVELOPMENT OF HYPOXIA-INDUCIBLE FACTOR 1α IN TISSUE ENGINEERED ANGIOGENESIS AND OSTEOGENESIS]. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2016; 30(4):504-8. View

17.

Wu C, Zhou Y, Chang J, Xiao Y . Delivery of dimethyloxallyl glycine in mesoporous bioactive glass scaffolds to improve angiogenesis and osteogenesis of human bone marrow stromal cells. Acta Biomater. 2013; 9(11):9159-68. DOI: 10.1016/j.actbio.2013.06.026. View

18.

Yao Q, Liu Y, Selvaratnam B, Koodali R, Sun H . Mesoporous silicate nanoparticles/3D nanofibrous scaffold-mediated dual-drug delivery for bone tissue engineering. J Control Release. 2018; 279:69-78. PMC: 5972066. DOI: 10.1016/j.jconrel.2018.04.011. View

19.

Quinlan E, Partap S, Azevedo M, Jell G, Stevens M, OBrien F . Hypoxia-mimicking bioactive glass/collagen glycosaminoglycan composite scaffolds to enhance angiogenesis and bone repair. Biomaterials. 2015; 52:358-66. DOI: 10.1016/j.biomaterials.2015.02.006. View

20.

Hadidi L, Constantin J, Dalisson B, Vieira D, Drager J, Harvey E . Biodegradable hypoxia biomimicry microspheres for bone tissue regeneration. J Biomater Appl. 2019; 34(7):1028-1037. DOI: 10.1177/0885328219884023. View